Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sysmex and QIAGEN Expand Collaboration in Genetic Testing

By LabMedica International staff writers
Posted on 07 Aug 2024

Sysmex Corporation (Kobe, Japan) has expanded its strategic alliance agreement with QIAGEN N. More...

V. (Venlo, The Netherlands) to deepen their cooperation in genetic testing, encompassing areas such as research and development, manufacturing, clinical development, and sales-marketing.

Sysmex has been a significant player in the in vitro diagnostics arena for over five decades, continually advancing its genetic testing capabilities. A key aspect of this advancement is the deployment of liquid biopsy technologies in product development to deliver personalized medicine solutions to both patients and healthcare professionals. With a robust global sales and service network backed by premier laboratories in Japan and the USA, Sysmex is dedicated to furthering the innovation of diagnostic technologies and high-value testing. Meanwhile, QIAGEN stands as a leader in precision medicine and a primary partner for pharmaceutical and biotech companies, developing companion diagnostics that identify genetic variances to inform clinical treatment decisions. QIAGEN’s technological suite ranges from polymerase chain reaction (PCR), multiplex PCR, digital PCR (dPCR), to next-generation sequencing (NGS), offering tailored solutions to over 30 global pharmaceutical partners through master collaboration agreements.

Since their initial alliance in 2013 and their decision to forge a strategic partnership for companion diagnostics in 2021, Sysmex and QIAGEN have seen considerable collaborative success. With the recent expansion of this partnership, the companies aim to leverage their combined expertise in genetic testing to produce high-value offerings for their global clientele. Under the new terms, Sysmex will integrate QIAGEN’s assays into the clinical trials it conducts for pharmaceutical companies and research institutions across its global network of laboratories, enhancing QIAGEN's global service capabilities.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dormant tumor cells evade imaging tests and may later reactivate to spread metastatic breast cancer (Photo courtesy of David A. Litman/Shutterstock)

MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.